$3.84 Billion is the total value of Artal Group S.A.'s 108 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RUBY | New | RUBIUS THERAPEUTICS, INC. | $69,811,000 | – | 2,908,791 | +100.0% | 1.82% | – |
| XBI | New | SPDR SERIES TRUSTcall | $19,174,000 | – | 200,000 | +100.0% | 0.50% | – |
| MU | New | MICRON TECHNOLOGY INCcall | $18,092,000 | – | 400,000 | +100.0% | 0.47% | – |
| C | New | CITIGROUP INCcall | $17,935,000 | – | 250,000 | +100.0% | 0.47% | – |
| BABA | New | ALIBABA GROUP HLDG LTDcall | $16,476,000 | – | 100,000 | +100.0% | 0.43% | – |
| WYNN | New | WYNN RESORTS LTDcall | $12,706,000 | – | 100,000 | +100.0% | 0.33% | – |
| AAL | New | AMERICAN AIRLS GROUP INCcall | $12,399,000 | – | 300,000 | +100.0% | 0.32% | – |
| BABA | New | ALIBABA GROUP HLDG LTDsponsored ads | $10,709,000 | – | 65,000 | +100.0% | 0.28% | – |
| NIO | New | NIO INCspon ads | $10,470,000 | – | 1,500,000 | +100.0% | 0.27% | – |
| REPL | New | REPLIMUNE GROUP INC | $7,245,000 | – | 450,000 | +100.0% | 0.19% | – |
| YI | New | 111 INCads | $6,084,000 | – | 450,000 | +100.0% | 0.16% | – |
| LOGM | New | LOGMEIN INC | $5,792,000 | – | 65,000 | +100.0% | 0.15% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $5,730,000 | – | 200,000 | +100.0% | 0.15% | – |
| YMAB | New | Y MABS THERAPEUTICS INC | $3,984,000 | – | 150,000 | +100.0% | 0.10% | – |
| ELAN | New | ELANCO ANIMAL HEALTH INC | $3,489,000 | – | 100,000 | +100.0% | 0.09% | – |
| FLEX | New | FLEX LTDord | $3,280,000 | – | 250,000 | +100.0% | 0.08% | – |
| CNAT | New | CONATUS PHARMACEUTICALS INC | $2,900,000 | – | 500,000 | +100.0% | 0.08% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $2,848,000 | – | 200,000 | +100.0% | 0.07% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-07 |
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.